778 completed, 333 terminated, 248 recruiting, 130 unknown. 1742 Phase 1, 587 Phase 2.
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | German Cancer Research Center | 12 | 2028-01-01 | 2025-03-14 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Universal CAR-T Cells Targeting AML CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-11-02 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-11-02 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
| CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia CLL-1-CD70 CAR-T Cell Injection - Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-11-30 | 2026-10-27 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-11-02 |
| ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS ATRN-119, Decitabine - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-30 | 2026-11-06 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-10-29 |
| A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML Biological SC-CAR.CLEC2Av1 - Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent | Phase 1 | Not yet recruiting | Seattle Children's Hospital | 20 | 2026-11-01 | 2026-11-02 |
Showing 20 of 1742. Sign in to see all of them.
Leukemia, Myeloid, Acute (1478) · Myelodysplastic Syndromes (531) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (412) · Leukemia (374) · Leukemia, Myelomonocytic, Chronic (232) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (231) · Recurrence (179) · Leukemia, Lymphocytic, Chronic, B-Cell (171) · Lymphoma, Non-Hodgkin (168) · Multiple Myeloma (154) · Blast Crisis (148) · Myeloproliferative Disorders (131) · Congenital Abnormalities (130) · Hodgkin Disease (123) · Lymphoma (113)
Hemic and Lymphatic Diseases (1741) · Neoplasms by Histologic Type (1736) · Hematologic Diseases (1729) · Neoplasms (1674) · Leukemia (1368) · Bone Marrow Diseases (871) · Pathologic Processes (732) · Pathological Conditions, Signs and Symptoms (732) · Disease Attributes (715) · Chronic Disease (577) · Immune System Diseases (550) · Immunoproliferative Disorders (541) · Lymphoproliferative Disorders (534) · Lymphatic Diseases (530)
Cytarabine (246) · Azacitidine (195) · venetoclax (162) · Cyclophosphamide (116) · fludarabine (113) · fludarabine phosphate (103) · Decitabine (98) · Filgrastim (66) · Idarubicin (55) · Daunorubicin (51) · Mitoxantrone (49) · Etoposide (47) · Granulocyte Colony-Stimulating Factor (47) · Busulfan (46) · Specimen Handling (46)
M.D. Anderson Cancer Center (128) · National Cancer Institute (NCI) (101) · Fred Hutchinson Cancer Center (45) · City of Hope Medical Center (37) · Novartis Pharmaceuticals (35) · Washington University School of Medicine (28) · Masonic Cancer Center, University of Minnesota (22) · Memorial Sloan Kettering Cancer Center (21) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (20) · AbbVie (19) · Massachusetts General Hospital (16) · Celgene (15) · Dana-Farber Cancer Institute (15) · Institute of Hematology & Blood Diseases Hospital, China (14) · St. Jude Children's Research Hospital (13)
United States (1236) · China (165) · France (129) · Germany (113) · Canada (104) · Spain (103) · Italy (85) · Australia (83) · United Kingdom (78) · South Korea (50) · Japan (48) · Netherlands (48) · Belgium (36) · Poland (22) · Israel (20)
Jorge Cortes, MD (13) · Farhad Ravandi-Kashani, MD (8) · Brenda Sandmaier (6) · Courtney DiNardo, MD (6) · Amir Fathi, MD (5)
PMID 42013378, PMID 32499241, PMID 38507688, PMID 16775234, PMID 23660685, PMID 27400247, PMID 28054442, PMID 28280089, PMID 28877686, PMID 31355467, PMID 33197925, PMID 33208914, PMID 33394722, PMID 33741715, PMID 33917201, PMID 34267079, PMID 34699069, PMID 35829925, PMID 37093350, PMID 39133921, PMID 39368878, PMID 39734743, PMID 40513054, PMID 41621809, PMID 41796974, PMID 10552943, PMID 10764422, PMID 11331327, PMID 11585760, PMID 12114413, PMID 12171484, PMID 12750167, PMID 14767498, PMID 15231574, PMID 15466934, PMID 15514371, PMID 15570084, PMID 15958631, PMID 16275934, PMID 16278404, PMID 16564913, PMID 16609072, PMID 16670265, PMID 16775235, PMID 16990776, PMID 17151364, PMID 17562873, PMID 17640728, PMID 17679729, PMID 17715389
P30CA033572 (28), P30CA015704 (21), 2023 (17), 2018 (16), P30CA006973 (16), P30CA016672 (14), U01CA070095 (12), 2015 (11), 2016 (11), U01CA076576 (11), U01CA062461 (10), 2017 (8), 2019 (8), P01CA018029 (8), 2025 (7)